Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials - 21/08/11
⁎ 
, Steven R. Steinhubl, MD b, Peter B. Berger, MD c, Alex I. Malinin, MD a, Jeffrey S. Baggish, MD d, Deepak L. Bhatt, MD e, Eric J. Topol, MD e, Dr. Serebruany's address is: 7600 Osler Drive, Suite 307, Towson, Maryland 21204Résumé |
We sought to compare the risk of hemorrhage due to the low (<100 mg), moderate (100 to 200 mg), and high (>200 mg) doses of aspirin (acetylsalicylic acid [ASA]) in 192,036 patients enrolled in 31 clinical trials. Despite substantial differences in the reporting patterns of bleeding complications, low-dose ASA was associated with the lowest risk, and moderate doses caused a relatively high hemorrhagic event rate, especially with regard to minor, gastrointestinal, and total bleeding, and stroke. These findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg.
Le texte complet de cet article est disponible en PDF.
Vol 95 - N° 10
P. 1218-1222 - mai 2005 Retour au numéro
Article précédent
- Barry Lewis Zaret, MD: A conversation With the Editor
- Myocardial Technetium-99m-Tetrofosmin Single-Photon Emission Computed Tomography Compared With 18F-Fluorodeoxyglucose Imaging to Assess Myocardial Viability
- Arend F.L. Schinkel, Jeroen J. Bax, Elena Biagini, Abdou Elhendy, Ron T. van Domburg, Roelf Valkema, Vittoria Rizzello, Olaf Schouten, Maarten Simoons, Don Poldermans
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?